Payment overview · 2025
General Payments
$55,456.79
148 reported records · 15 companies
Healthcare provider profile · identity verified
Curtis Linjer Chen, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · BRONX, NY · NPI 1083334619
Verified facts
What the public records show
CMS Open Payments records show Curtis Linjer Chen, PA-C received $55,456.79 in general payments during 2025 across 148 reported records.
Galderma Laboratories, L.P. accounted for 32.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Adbry, Opzelura, Vtama, Winlevi, Zoryve.
Arcutis Biotherapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Zoryve as an associated drug or biological on 56906 records involving 10745 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Zoryve by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPZELURA as an associated drug or biological on 59568 records involving 12571 distinct recipient NPIs. Public Medicare Part D data also shows 235 claims for Opzelura by this doctor in 2024.
Kowa Pharmaceuticals America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZORYVE as an associated drug or biological on 22731 records involving 10996 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Zoryve by this doctor in 2024.
LEO Pharma Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ADBRY as an associated drug or biological on 37730 records involving 9327 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Adbry by this doctor in 2024.
Organon LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VTAMA as an associated drug or biological on 29859 records involving 10220 distinct recipient NPIs. Public Medicare Part D data also shows 270 claims for Vtama by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EUCRISA as an associated drug or biological on 1712 records involving 991 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Eucrisa by this doctor in 2024.
SUN PHARMACEUTICAL INDUSTRIES INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Winlevi as an associated drug or biological on 15122 records involving 6094 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Winlevi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $17,935.10 | 32.3% | 44 | 2025 |
| Arcutis Biotherapeutics, Inc. | Unresolved — no canonical attribution shown | $15,782.71 | 28.5% | 34 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $10,000.19 | 18.0% | 17 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $7,631.74 | 13.8% | 16 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $1,611.92 | 2.9% | 7 | 2025 |
| LEO Pharma Inc. | Unresolved — no canonical attribution shown | $1,317.39 | 2.4% | 8 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $335.98 | 0.6% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $275.36 | 0.5% | 5 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $146.96 | 0.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $140.15 | 0.2% | 3 | 2025 |
| Botanix SB Inc | Unresolved — no canonical attribution shown | $126.39 | 0.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $71.90 | 0.1% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $38.93 | 0.1% | 2 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $22.57 | 0.0% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $19.50 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $22,050.00 | 14 |
| Consulting Fee | $16,107.50 | 13 |
| Travel and Lodging | $11,609.90 | 37 |
| Food and Beverage | $4,589.39 | 83 |
| Honoraria | $1,100.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZORYVE Normalized: zoryve |
Drug | Arcutis Biotherapeutics, Inc., Kowa Pharmaceuticals America, Inc. | $23,414.45 | 50 | 2025 |
Source payment records
|
|||||
| NEMLUVIO Normalized: nemluvio |
Drug | Galderma Laboratories, L.P. | $17,935.10 | 44 | 2025 |
Source payment records
|
|||||
| VTAMA Normalized: vtama |
Drug | Organon LLC | $10,000.19 | 17 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $335.98 | 7 | 2025 |
Source payment records
|
|||||
| ANZUPGO Normalized: anzupgo |
Drug | LEO Pharma Inc. | $303.84 | 4 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $181.45 | 3 | 2025 |
Source payment records
|
|||||
| ADBRY Normalized: adbry |
Biological | LEO Pharma Inc. | $156.47 | 2 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $146.96 | 1 | 2025 |
Source payment records
|
|||||
| SOFDRA Normalized: sofdra |
Drug | Botanix SB Inc | $126.39 | 1 | 2025 |
Source payment records
|
|||||
| LITFULO Normalized: litfulo |
Drug | PFIZER INC. | $117.62 | 2 | 2025 |
Source payment records
|
|||||
| OPZELURA Normalized: opzelura |
Drug | Incyte Corporation | $77.04 | 3 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $71.90 | 1 | 2025 |
Source payment records
|
|||||
| CIBINQO Normalized: cibinqo |
Drug | PFIZER INC. | $46.22 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $38.93 | 2 | 2025 |
Source payment records
|
|||||
| Winlevi Normalized: winlevi |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $22.57 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ADBRY adbry |
2025 | Adbry | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OPZELURA opzelura |
2025 | Opzelura | 2024 | 235 | exact normalized | Medicare Part D |
| VTAMA vtama |
2025 | Vtama | 2024 | 270 | exact normalized | Medicare Part D |
| Winlevi winlevi |
2025 | Winlevi | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZORYVE zoryve |
2025 | Zoryve | 2024 | 150 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Arcutis Biotherapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Zoryve open payments reported associated product |
CMS Open Payments — General Payments 56906 supporting records · 10745 recipient NPIs · example record 1252324094 |
Zoryve · 2024 Exact normalized brand match · 1 Part D row |
150 | 46 |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | OPZELURA open payments reported associated product |
CMS Open Payments — General Payments 59568 supporting records · 12571 recipient NPIs · example record 1225959946 |
Opzelura · 2024 Exact normalized brand match · 1 Part D row |
235 | 50 |
| Kowa Pharmaceuticals America, Inc. Exact reporting entity; no affiliate inference |
2025 | ZORYVE open payments reported associated product |
CMS Open Payments — General Payments 22731 supporting records · 10996 recipient NPIs · example record 1243071225 |
Zoryve · 2024 Exact normalized brand match · 1 Part D row |
150 | 46 |
| LEO Pharma Inc. Exact reporting entity; no affiliate inference |
2025 | ADBRY open payments reported associated product |
CMS Open Payments — General Payments 37730 supporting records · 9327 recipient NPIs · example record 1251989155 |
Adbry · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Organon LLC Exact reporting entity; no affiliate inference |
2025 | VTAMA open payments reported associated product |
CMS Open Payments — General Payments 29859 supporting records · 10220 recipient NPIs · example record 1237634330 |
Vtama · 2024 Exact normalized brand match · 1 Part D row |
270 | 44 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | EUCRISA open payments reported associated product |
CMS Open Payments — General Payments 1712 supporting records · 991 recipient NPIs · example record 1228794851 |
Eucrisa · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. Exact reporting entity; no affiliate inference |
2025 | Winlevi open payments reported associated product |
CMS Open Payments — General Payments 15122 supporting records · 6094 recipient NPIs · example record 1250962443 |
Winlevi · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ketoconazole | Ketoconazole | 678 | 132 |
| Ammonium Lactate | Ammonium Lactate | 642 | 182 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 427 | 202 |
| Mupirocin | Mupirocin | 297 | 140 |
| Vtama | Tapinarof | 270 | 44 |
| Opzelura | Ruxolitinib Phosphate | 235 | 50 |
| Clindamycin Phosphate | Clindamycin Phosphate | 214 | 72 |
| Fluocinonide | Fluocinonide | 200 | 63 |
| Jublia | Efinaconazole | 166 | 40 |
| Halobetasol Propionate | Halobetasol Propionate | 154 | 84 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 151 | 37 |
| Zoryve | Roflumilast | 150 | 46 |
| Tacrolimus | Tacrolimus | 128 | 49 |
| Hydrocortisone | Hydrocortisone | 119 | 45 |
| Clobetasol Propionate | Clobetasol Propionate | 116 | 43 |
| Dupixent Pen | Dupilumab | 94 | 16 |
| Tretinoin | Tretinoin | 72 | 21 |
| Ciclopirox | Ciclopirox Olamine | 60 | 19 |
| Ertaczo | Sertaconazole Nitrate | 56 | suppressed |
| Cabtreo | Adapalene/Benzoyl/Clindamycin | 55 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 52 | suppressed |
| Arazlo | Tazarotene | 35 | 13 |
| Calcipotriene | Calcipotriene | 32 | 13 |
| Pimecrolimus | Pimecrolimus | 32 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 27 | 18 |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 27 | suppressed |
| Metronidazole | Metronidazole | 24 | 11 |
| Nystatin | Nystatin | 22 | suppressed |
| Minoxidil | Minoxidil | 20 | suppressed |
| Adbry | Tralokinumab-Ldrm | 18 | suppressed |
| Ciclopirox | Ciclopirox | 18 | suppressed |
| Winlevi | Clascoterone | 17 | suppressed |
| Crotan | Crotamiton | 16 | suppressed |
| Duobrii | Halobetasol Propion/Tazarotene | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Eucrisa | Crisaborole | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $55,456.79 · 148 records | Galderma Laboratories, L.P. | ADBRY, ANZUPGO, Bimzelx, CIBINQO, COSENTYX, DUPIXENT, LITFULO, NEMLUVIO, Natroba, OPZELURA, RINVOQ, SKYRIZI, SOFDRA, Spinosad, TREMFYA, VTAMA, Winlevi, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Adbry play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Arcutis Biotherapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error